An Extension of the TG1101-RMS201 Trial

Completed · Phase 2

Conditions studied: Relapsing Remitting Multiple Sclerosis

In brief

This study evaluates the long term use of a single agent ublituximab, a novel monoclonal antibody, in patients with relapsing forms of multiple sclerosis

Key facts

Study ID

NCT03381170

Run by

TG Therapeutics, Inc.

People needed

48

Starts

2017-06-01

Expected to finish

2022-11-11

Last updated by the study team

2022-12-21

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects currently enrolled in TG1101-RMS201 trial
• Subjects who have completed three infusions of ublituximab (at Day 1, Day 15, and Week24, as specified in the TG1101-RMS201 protocol) and have completed the scheduled assessments up to the final 48-week visit

You may not qualify if…

• Subjects who discontinued ublituximab treatment or withdrew consent from the TG1101- RMS201 study during the 48-week evaluation period
• Subjects who have started any other immunomodulating or disease modifying therapy after completion of the TG1101-RMS201 trial
• Pregnant or nursing mothers

Where it is running

• TG Therapeutics Investigational Trial Site — Pasadena, California, United States
• TG Therapeutics Investigational Trial Site — Aurora, Colorado, United States
• TG Therapeutics Investigational Trial Site — Lexington, Kentucky, United States
• TG Therapeutics Investigational Trial Site — Columbus, Ohio, United States
• TG Therapeutics Investigational Trial Site — Westerville, Ohio, United States
• TG Therapeutics Investigational Trial Site — Knoxville, Tennessee, United States
• TG Therapeutics Investigational Trial Site — Round Rock, Texas, United States
• TG Therapeutics Investigational Trial Site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.